Can Anything Else Revolutionize The Molecular Targeted Cancer Therapies Market?DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c75622) has announced the addition of "Pipeline Insight: Molecular Targeted Cancer Therapies: Can Anything Else Revolutionize rev·o·lu·tion·ize tr.v. rev·o·lu·tion·ized, rev·o·lu·tion·iz·ing, rev·o·lu·tion·iz·es 1. To bring about a radical change in: Television has revolutionized news coverage. 2. the Market?" to their offering. Introduction Approaches to cancer treatment continue to incorporate molecular targeted therapies into standard treatment regimens. With an increasing number of candidates gaining approval, and with a dynamic developmental pipeline, further clinical, commercial and strategic challenges are continuing to emerge. Scope - Research and analysis of the MTT MTT 3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide MTT Machine Tool Technology MTT Microwave Theory and Techniques MTT Mobile Task Team MTT Multi-Table Tournament (poker) pipeline with in-depth clinical and commercial assessment of Phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA candidates - Seven major pharmaceutical market sales forecasts Sales forecast A key input to a firm's financial planning process. External sales forecasts are based on historical experience, statistical analysis, and consideration of various macroeconomic factors. to 2016 for key pipeline candidates incorporating product specific assumptions and events - Segmentation and examination of product pipeline by developmental phase, class, mode of action, indication and developer - Insight and analysis of market potential including commercial opportunity, commonalities across cancers and discussion of unmet needs Highlights 329 different pipeline candidates have been identified of which 24 are in late-phase development. These identified candidates have a forecast sales potential of up to $6.03 billion in the seven major pharmaceutical markets by 2016. Among agents with the greatest commercial potential are the angiogenesis inhibitors angiogenesis inhibitor Oncology A chemotherapy adjuvant which inhibits the angiogenesis required for tumor growth and survive, especially for metastastatic tumors See CAI, CM101, IFN-alpha, IL-12, Marimastat, Pentosan polysulfate, Platelet factor 4, Thalidomide, TNP-470. Recentin (cediranib; AstraZeneca), aflibercept (VEGF-Trap; Regeneron/Sanofi-Aventis) and pazopanib (GlaxoSmithKline). Other candidates holding particular promise include the only preregistered agent Novartiss Gleevec-follow-on Tasigna (nilotinib), Novartiss mTOR inhibitor Certican (everolimus), and Biogen Idecs Biogen Idec, Inc. (NASDAQ: BIIB) is a biotechnology company specializing in drugs for neurological disorders, autoimmune disorders and cancer. The company was formed in 2003 by the merger of Cambridge, Massachusetts-based Biogen and San Diego, California-based Idec anti-CD23 monoclonal antibody monoclonal antibody, an antibody that is mass produced in the laboratory from a single clone and that recognizes only one antigen. Monoclonal antibodies are typically made by fusing a normally short-lived, antibody-producing B cell (see immunity) to a fast-growing , lumiliximab. Reasons to Purchase - Acquire a detailed appreciation and impartial perspective of the entire molecular targeted therapies developmental pipeline - Identify the key products in late-phase development based on sales forecasts to 2016 and the drug assessment methodology - Assess the shifting oncology market dynamic and how future treatment of many cancers will incorporate pipeline products For more information, visit http://www.researchandmarkets.com/reports/c75622 Source: Datamonitor |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion